Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only four biologics—Amgen’s Enbrel, Janssen’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent patients with psoriasis. Although topical corticosteroids continue to be the mainstay of pediatric treatment, the use of biologics is increasing, especially in the later lines, owing to the more-frequent and severe adverse events associated with long-term use of topical corticosteroids in children. Thus, there remains a significant unmet need for efficacious therapies with better safety profiles for this psoriasis subpopulation.
Markets covered: United States.
Key companies: AbbVie, Amgen, Astellas, Bausch Health, Eli Lilly, Janssen, Novartis.
Key drugs: Cosentyx, Elidel, Enbrel, Humira, Protopic, Stelara, Taclonex, Taltz, Tremfya.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.